The House Committee on Oversight and Reform has launched a wide-ranging investigation into prescription drug pricing in the United States.
Yesterday, the House Committee on Oversight and Reform launched a wide-ranging investigation into prescription drug pricing in the United States.
The committee’s chair, Representative Elijah Cummings, D-Maryland, sent letters to 12 drug makers seeking information and documents related to pricing practices. According to the committee’s statement, the letters seek further information about price increases, investments in research and development, and corporate strategies to defend market share. The committee will next hold a series of hearings on drug pricing.
“The Committee on Oversight and Reform is investigating the actions of drug companies in raising prescription drug prices in the United States, as well as the effects of these actions on federal and state budgets and on American families,” Cummings wrote in a statement announcing the investigation. “For years, drug companies have been aggressively increasing prices on existing drugs and setting higher launch prices for new drugs while recording windfall profits. The goals of this investigation are to determine why drug companies are increasing prices so dramatically, how drug companies are using the proceeds, and what steps can be taken to reduce prescription drug prices.”
Among the products that are subject to the investigation are AbbVie’s brand-name adalimumab, Humira; Amgen’s etanercept, Enbrel; and Sanofi’s insulin glargine, Lantus. All 3 of these products are the targets of as-yet unrealized biosimilar and follow-on competition:
Additional products that are subject to the committee’s investigation are cancer drugs imatinib (Novartis’ Gleevec) and lenalidomide (Celgene’s Revlimid), pain drug pregabalin (Pfizer’s Lyrica), and glatiramer acetate (Teva’s Copaxone), among others.